Drug Trial Radar · NCT06451588
Fecal Microbiota Transplantation in Axial Spondyloarthritis
Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
99
Planned (sponsor's estimate)
Start
Jun 1, 2024
Primary completion
May 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- University Hospital of North NorwayAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Helse Nord
- First posted
- Jun 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Although biologic therapy have revolutionized the treatment of Spondyloarthrtitis (SpA), many patients do not experience complete relief of SpA related complaints. It has been established that patients with SpA have an altered composition of microorganisms (microbiota) in the gut compared to healthy controls, and that this correlates to disease activity and respons to therapy. The goal of this randomized double-blind study is to evaluate the efficacy of fecal microbiota transplantation (FMT) in patients with axial SpA with a suboptimal effect of biologic therapy. The main questions it aims to answer are: * Can FMT reduce disease activity in axial SpA? * Can FMT alleviate pain and reduce fatigue in axial SpA? * Is the composition of microorganisms restored to normal in patients with SpA after a treatment with FMT? Participants will receive a single treatment in the form of an enema with either donor FMT or placebo at baseline. The primary endpoint will be evaluated after 90 days, but efficacy and safety will be monitored from baseline until 365 days.
Conditions
- Axial Spondyloarthritis
- Ankylosing Spondylitis
- Dysbiosis
- Spondyloarthritis
- Spondylitis
- Arthritis
- Musculoskeletal Diseases
- Spinal Disease
- Joint Diseases
Interventions
FMTDrug
Active FMT
PlaceboDrug
The placebo treatment will be prepared based on the patients' fecal samples (autologous).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Minimal Clinically Important ImprovementTime frame: 90 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital North Norway
Tromsø, Norway · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.